DK1156119T3 - Anti-cancer gene therapy by modulating the immune response and / or the inflammatory response - Google Patents
Anti-cancer gene therapy by modulating the immune response and / or the inflammatory responseInfo
- Publication number
- DK1156119T3 DK1156119T3 DK01110326T DK01110326T DK1156119T3 DK 1156119 T3 DK1156119 T3 DK 1156119T3 DK 01110326 T DK01110326 T DK 01110326T DK 01110326 T DK01110326 T DK 01110326T DK 1156119 T3 DK1156119 T3 DK 1156119T3
- Authority
- DK
- Denmark
- Prior art keywords
- agent
- contg
- modulating
- genome
- inflammatory response
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2033—IL-5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/204—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Use of a viral vector contg. in its genome a DNA fragment (I) contg. ≥ 1 gene encoding all or part of an agent (A) that modulates the immune and/or inflammatory response for the treatment of cancer in mammals is new. (A) can be a cell surface co-stimulatory molecule, a chemokine, a monoclonal antibody against a lymphocyte surface maker, a super antigen characteristic of an infectious organism (bacterium, virus or parasite), a polypeptide with adjuvant activity or esp. a cytokine. Also claimed is the use of a viral vector with positive tropism for cancer cells contg. in its genome a DNA fragment including ≥ 1 gene, encoding an agent able to destroy cancer cells, under control of appropriate expression elements, for selective delivery of the agent to cancerous tumours.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9311601A FR2710536B1 (en) | 1993-09-29 | 1993-09-29 | Anti-cancer use of a viral vector comprising a gene which modulates the immune and / or inflammatory response. |
EP94928924A EP0721510B1 (en) | 1993-09-29 | 1994-09-28 | Anti-cancer gene therapy by modulation of immune or inflammatory response |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1156119T3 true DK1156119T3 (en) | 2006-06-06 |
Family
ID=9451366
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK94928924T DK0721510T3 (en) | 1993-09-29 | 1994-09-28 | Anti-cancer gene therapy by modulating the immune response and / or the inflammatory response |
DK01110326T DK1156119T3 (en) | 1993-09-29 | 1994-09-28 | Anti-cancer gene therapy by modulating the immune response and / or the inflammatory response |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK94928924T DK0721510T3 (en) | 1993-09-29 | 1994-09-28 | Anti-cancer gene therapy by modulating the immune response and / or the inflammatory response |
Country Status (12)
Country | Link |
---|---|
EP (2) | EP1156119B9 (en) |
JP (1) | JP4094053B2 (en) |
AT (2) | ATE323774T1 (en) |
AU (1) | AU709336C (en) |
DE (2) | DE69434708T2 (en) |
DK (2) | DK0721510T3 (en) |
ES (2) | ES2204922T3 (en) |
FR (1) | FR2710536B1 (en) |
HK (1) | HK1042728B (en) |
PT (2) | PT1156119E (en) |
SG (1) | SG96534A1 (en) |
WO (1) | WO1995009241A2 (en) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5833975A (en) * | 1989-03-08 | 1998-11-10 | Virogenetics Corporation | Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence |
US5662896A (en) | 1988-03-21 | 1997-09-02 | Chiron Viagene, Inc. | Compositions and methods for cancer immunotherapy |
US6093700A (en) | 1995-05-11 | 2000-07-25 | Thomas Jefferson University | Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF |
DE69535288T2 (en) * | 1994-05-13 | 2007-04-05 | Thomas Jefferson University | METHOD FOR INDUCING AN IMMUNE RESPONSE TO RECOMBINANT VACCINIA VIRUSES EXPRESSING THE GM-CSF GENE |
US6045802A (en) * | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
US6165460A (en) * | 1995-07-10 | 2000-12-26 | Therion Biologics Corporation | Generation of immune responses to prostate-specific antigen (PSA) |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
GB2324960A (en) * | 1997-05-09 | 1998-11-11 | Univ Manchester | Delivery of naked DNA for wound healing |
CA2308606A1 (en) | 1997-11-06 | 1999-05-20 | Chiron S.P.A. | Neisserial antigens |
AU1979599A (en) | 1998-01-14 | 1999-08-02 | Chiron S.P.A. | (neisseria meningitidis) antigens |
BR9910089A (en) | 1998-05-01 | 2004-06-08 | Chiron Corp | Compositions and antigens of neisseria meningitidis |
RU2245366C2 (en) | 1999-04-30 | 2005-01-27 | Чирон С.Р.Л. | Neisseria antigen, nucleic acid encoding its, their applying |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
EP2275552B1 (en) | 1999-10-29 | 2015-09-09 | GlaxoSmithKline Biologicals SA | Neisserial antigenic peptides |
PT2289545T (en) | 2000-01-17 | 2016-09-06 | Glaxosmithkline Biologicals Sa | Supplemented omv vaccine against meningococcus |
MXPA03003690A (en) | 2000-10-27 | 2004-05-05 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a b. |
EP1366167A2 (en) * | 2001-01-26 | 2003-12-03 | Transgene S.A. | Biological organism for preparing pharmaceutical compositions for treating mammals |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
EP1281767A3 (en) | 2001-07-31 | 2003-05-28 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of tumors |
ES2312649T3 (en) | 2001-12-12 | 2009-03-01 | Novartis Vaccines And Diagnostics S.R.L. | IMMUNIZATION AGAINST CHLAMYDIA TRACHOMATIS. |
EP1369491A1 (en) | 2002-06-05 | 2003-12-10 | Aladar A. Szalay | Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue |
JP4634710B2 (en) * | 2002-07-31 | 2011-02-16 | ゲネルクス コーポレーション | Microorganisms and cells for tumor diagnosis and treatment |
WO2004010957A2 (en) | 2002-07-31 | 2004-02-05 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
DE602004018927D1 (en) | 2003-06-18 | 2009-02-26 | Genelux Corp | MODIFIED RECOMBINANT VACCINIA VIRUSES, USES THEREOF |
PT1736541E (en) | 2004-03-29 | 2013-01-31 | Galpharma Co Ltd | Novel modified galectin 9 protein and use thereof |
WO2007030668A2 (en) * | 2005-09-07 | 2007-03-15 | Jennerex Biotherapeutics Ulc | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
RU2313349C2 (en) * | 2006-01-16 | 2007-12-27 | Михаил Аркадьевич Шурдов | Method for treating oncological diseases |
US20110206692A1 (en) | 2006-06-09 | 2011-08-25 | Novartis Ag | Conformers of bacterial adhesins |
US8052968B2 (en) | 2006-10-16 | 2011-11-08 | Genelux Corporation | Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
BRPI1007744A2 (en) | 2009-05-12 | 2017-06-27 | Transgene Sa | method for the production and purification of a wild-type orthopoxvirus, wild-type orthopoxvirus, pharmaceutical composition, use of a wild-type orthopoxvirus and use of an immortalized avian cell line |
AU2010275764A1 (en) | 2009-07-21 | 2012-03-15 | Transgene Sa | Enzymatic composition for the digestion of chicken embryos |
TWI690322B (en) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | Virus-containing formulation and use thereof |
CN107206063B (en) | 2014-12-01 | 2021-09-28 | 特兰斯吉恩股份有限公司 | Stable liquid vaccinia virus formulations |
WO2018211419A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
EP3624851A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2583429B1 (en) * | 1985-06-18 | 1989-11-03 | Transgene Sa | INTERFERON U EXPRESSION VECTOR IN MAMMALIAN CELLS, PROCESS FOR IMPLEMENTING SAME AND PRODUCT OBTAINED, AND PHARMACEUTICAL COMPOSITION CONTAINING INTERFERON U |
FR2583770B1 (en) * | 1985-06-21 | 1988-08-19 | Transgene Sa | EXPRESSION OF HUMAN IL-2 IN MAMMALIAN CELLS BY A RECOMBINANT POXVIRUS |
US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
EP1216710B1 (en) * | 1991-10-04 | 2006-04-05 | Whitehead Institute For Biomedical Research | Regulation of systemic immune responses utilizing cytokines and antigens |
ES2144426T3 (en) * | 1991-10-25 | 2000-06-16 | Sidney Kimmel Cancer Ct | GENE LYMPHOCEMICAL THERAPY OF CANCER IN COMBINATION WITH TUMOR ANTIGENS. |
US5314813A (en) * | 1992-02-19 | 1994-05-24 | Scripps Research Institute | Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines |
FR2688514A1 (en) * | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them |
WO1994004196A1 (en) * | 1992-08-14 | 1994-03-03 | Imperial Cancer Research Technology Limited | Tumour therapy |
-
1993
- 1993-09-29 FR FR9311601A patent/FR2710536B1/en not_active Expired - Fee Related
-
1994
- 1994-09-28 SG SG9608019A patent/SG96534A1/en unknown
- 1994-09-28 AU AU78159/94A patent/AU709336C/en not_active Expired
- 1994-09-28 DK DK94928924T patent/DK0721510T3/en active
- 1994-09-28 ES ES94928924T patent/ES2204922T3/en not_active Expired - Lifetime
- 1994-09-28 AT AT01110326T patent/ATE323774T1/en active
- 1994-09-28 WO PCT/FR1994/001133 patent/WO1995009241A2/en active IP Right Grant
- 1994-09-28 JP JP51015095A patent/JP4094053B2/en not_active Expired - Lifetime
- 1994-09-28 AT AT94928924T patent/ATE247714T1/en active
- 1994-09-28 ES ES01110326T patent/ES2260117T3/en not_active Expired - Lifetime
- 1994-09-28 PT PT01110326T patent/PT1156119E/en unknown
- 1994-09-28 DE DE69434708T patent/DE69434708T2/en not_active Expired - Lifetime
- 1994-09-28 DE DE69433060T patent/DE69433060T2/en not_active Expired - Lifetime
- 1994-09-28 EP EP01110326A patent/EP1156119B9/en not_active Expired - Lifetime
- 1994-09-28 PT PT94928924T patent/PT721510E/en unknown
- 1994-09-28 DK DK01110326T patent/DK1156119T3/en active
- 1994-09-28 EP EP94928924A patent/EP0721510B1/en not_active Expired - Lifetime
-
2002
- 2002-05-21 HK HK02103801.1A patent/HK1042728B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU709336B2 (en) | 1999-08-26 |
HK1042728B (en) | 2006-11-24 |
HK1042728A1 (en) | 2002-08-23 |
EP0721510A1 (en) | 1996-07-17 |
DE69434708T2 (en) | 2007-04-05 |
DK0721510T3 (en) | 2003-11-17 |
WO1995009241A2 (en) | 1995-04-06 |
ES2260117T3 (en) | 2006-11-01 |
FR2710536B1 (en) | 1995-12-22 |
ATE323774T1 (en) | 2006-05-15 |
EP1156119B1 (en) | 2006-04-19 |
DE69433060T2 (en) | 2004-06-03 |
AU7815994A (en) | 1995-04-18 |
EP1156119B9 (en) | 2006-08-30 |
SG96534A1 (en) | 2003-06-16 |
AU709336C (en) | 2002-06-13 |
JP4094053B2 (en) | 2008-06-04 |
EP1156119A2 (en) | 2001-11-21 |
EP1156119A3 (en) | 2002-10-23 |
PT721510E (en) | 2003-11-28 |
DE69434708D1 (en) | 2006-05-24 |
PT1156119E (en) | 2006-08-31 |
FR2710536A1 (en) | 1995-04-07 |
ATE247714T1 (en) | 2003-09-15 |
EP0721510B1 (en) | 2003-08-20 |
ES2204922T3 (en) | 2004-05-01 |
DE69433060D1 (en) | 2003-09-25 |
WO1995009241A3 (en) | 1995-06-22 |
JPH09502993A (en) | 1997-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0721510T3 (en) | Anti-cancer gene therapy by modulating the immune response and / or the inflammatory response | |
AU672195B2 (en) | Defective recombinant adenoviruses expressing cytokines for use in antitumoral treatment | |
DE69233186D1 (en) | KARCINOEMBRYONAL ANTIGENT EXPECTING RECOMBINANT VIRUSES AND METHODS OF USE | |
AU7789987A (en) | Recombinant vaccine | |
ATE188740T1 (en) | VIRUS PARTICLES WITH ALTERED HOST SPECTRUM | |
GR3032660T3 (en) | Lymphokine gene therapy of cancer. | |
EP1669454A3 (en) | Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma | |
DE3585578D1 (en) | HEPATITIS SURFACE ANTI-PARTICLE VACCINE. | |
DK498387A (en) | Viral DNA SEQUENCE | |
Wilczyńska et al. | Combined delivery of an antiangiogenic protein (angiostatin) and an immunomodulatory gene (interleukin-12) in the treatment of murine cancer. | |
ATE229983T1 (en) | MASPIN- A NEW SERPIN WITH TUMOR SUPPRESSING ACTIVITY | |
Kaufman | Manipulating the local tumor microenvironment with poxviruses expressing costimulatory molecules | |
Lonai et al. | Experiments on the physiological regulation of the H-2 complex | |
Leng et al. | Effects of γ‐interferon gene‐modified hepatocytes on murine implanted liver carcinoma | |
Lee et al. | Ribonuclease activity in highly purified α-lymphotoxin | |
Capone | PASSIVE IMMUNOTHERAPY OF HUMAN BREAST TUMORS WITH MONOCLONAL ANTIBODIES. | |
SU1380209A1 (en) | RECOMBINANT PLASMID DNA PUR 291-HAV 22 ENCODING SYNTHESIS OF HYBRID POLYPEPTIDE OF HEPATITIS VIRUS A ANTIGENIC DETERMINANTS WITH β-GALACTOSIDASE |